Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns ...

EDP-323 significantly reduced mean viral load AUC by 85% and 87% in the high- and low-dose groups, respectively, compared ...

A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous ...

Ventyx Biosciences Inc. (NASDAQ:VTYX) is one of the best NASDAQ stocks under $5 to buy now. On October 22, Ventyx Biosciences ...

Inflammatory arthritis resulting from immune checkpoint inhibitor use is immunologically unique and likely driven by T cells ...

ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY ( NCT06659445) trial evaluating ...

SUDO-550 demonstrated favorable safety, tolerability, and once-daily pharmacokinetic profile with full central nervous system (CNS) penetration - Achieved exposure levels associated with >90% ...

Results from the trial's first year were reported at the 2024 ACR meeting, and they persuaded the FDA to approve the drug for ...

The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...

The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

The researchers found that the weighted incidence rate was 51.90 and 58.41 per 100,000 person-years in individuals initiating SGLT-2 inhibitors and sulfonylureas, respectively.

New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relacorilant plus nab-paclitaxel showed a PFS benefit in patients with ...